Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 8/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 4/20 | 0.38 |
| ▸ | FADS1 | O60427 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16119992 | 0.91 | FADS1 (0.41) | PRMT1CARM1FADS1PRMT5WDR77 | |
| SCHEMBL16120045 | 0.90 | TTK (0.39) | PRMT1CARM1LTA4HSIGMAR1 | |
| SCHEMBL17469449 | 0.90 | PRMT1 (0.37) | PRMT1CARM1PRMT5WDR77HTR2A | |
| SCHEMBL17469509 | 0.90 | PRMT1 (0.43) | PRMT1FADS1PRMT5WDR77HTR2A | |
| SCHEMBL17469503 | 0.87 | PRMT1 (0.46) | PRMT1CARM1 | |
| SCHEMBL17469502 | 0.86 | LRRK2 (0.40) | PRMT5WDR77SLC6A4KCNH2 | |
| SCHEMBL17469508 | 0.86 | PRMT1 (0.41) | PRMT1SLC6A4MTNR1AMTNR1B | |
| SCHEMBL17469478 | 0.85 | CARM1 (0.42) | PRMT1CARM1PRMT5WDR77HTR2A | |
| SCHEMBL17469504 | 0.85 | HTR2A (0.44) | PRMT1FADS1HTR2ASLC6A4MTNR1A | |
| SCHEMBL17469470 | 0.85 | HSP90AA1 (0.37) | PRMT1CARM1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105497-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2018-04-19 | — | — | US | disclosed |
| US-9765035-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160024017-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024017-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | PRMT1 1/4885CARM1 12/4885FADS1 2222/4885 |
| US-20180105497-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | PRMT1 1/4885CARM1 12/4885FADS1 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.